Enanta Pharmaceuticals
ENTA
129 hedge funds and large institutions have $296M invested in Enanta Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 49 increasing their positions, 47 reducing their positions, and 34 closing their positions.
70% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $614K
4% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 152 → 129 (-23)
29% less capital invested
Capital invested by funds: $414M → $296M (-$118M)
59% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$14.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$14.1M |
| 3 |
AC
Armistice Capital
New York
|
+$6.28M |
| 4 |
SIM
Spark Investment Management
New York
|
+$5.77M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$3.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$7.33M |
| 2 |
AAM
Aureus Asset Management
Boston,
Massachusetts
|
-$4.89M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$4.73M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.08M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.96M |
ENTA Hedge Fund Activity: Q2 2016 in Review
129 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2016, worth a combined $296M — down 29% from $414M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ENTA and 14 opened new positions — a net loss of 20 holders — while 47 trimmed existing stakes and 49 added.
The largest buyer was Fiera Capital (Canada), opening a new position worth an estimated $14.8M. The largest seller was OrbiMed, exiting entirely with an estimated $7.33M sold.
- 129 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2016, down from 152 in Q1 2016.
- Funds reported $296M of Enanta Pharmaceuticals stock for Q2 2016, down 29% quarter-over-quarter.
- 14 funds opened new Enanta Pharmaceuticals positions in Q2 2016 and 34 closed out, a net change of -20 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2016 was Fiera Capital (Canada), an estimated $14.8M added.
- The largest Enanta Pharmaceuticals seller in Q2 2016 was OrbiMed, an estimated $7.33M sold.
Based on aggregated 13F filings for Q2 2016.